Market Closed -
Nasdaq
01:30:00 29/06/2024 am IST
|
5-day change
|
1st Jan Change
|
6.9
USD
|
-7.38%
|
|
-13.32%
|
-45.88%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
56.44
|
691.8
|
436.1
|
53.02
|
75.01
|
40.67
|
-
|
-
|
Enterprise Value (EV)
1 |
56.44
|
691.8
|
436.1
|
53.02
|
75.01
|
40.67
|
40.67
|
40.67
|
P/E ratio
|
-1.75
x
|
-13.4
x
|
-9.52
x
|
-0.9
x
|
-1.42
x
|
-1.12
x
|
-1.5
x
|
-1.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
63.8
x
|
40.9
x
|
5.22
x
|
7.48
x
|
4.63
x
|
4.62
x
|
3.83
x
|
EV / Revenue
|
-
|
63.8
x
|
40.9
x
|
5.22
x
|
7.48
x
|
4.63
x
|
4.62
x
|
3.83
x
|
EV / EBITDA
|
-
|
-
|
-10.4
x
|
-1
x
|
-
|
-0.83
x
|
-0.74
x
|
-0.66
x
|
EV / FCF
|
-
|
-
|
-11.6
x
|
-
|
-1.95
x
|
-0.87
x
|
-0.74
x
|
-0.68
x
|
FCF Yield
|
-
|
-
|
-8.63%
|
-
|
-51.2%
|
-116%
|
-135%
|
-148%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,660
|
4,223
|
4,580
|
4,820
|
5,883
|
5,894
|
-
|
-
|
Reference price
2 |
34.00
|
163.8
|
95.20
|
11.00
|
12.75
|
6.900
|
6.900
|
6.900
|
Announcement Date
|
19/03/20
|
16/03/21
|
24/02/22
|
13/03/23
|
08/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
10.84
|
10.65
|
10.16
|
10.02
|
8.783
|
8.795
|
10.63
|
EBITDA
1 |
-
|
-
|
-41.91
|
-52.79
|
-
|
-49
|
-55
|
-61.42
|
EBIT
1 |
-
|
-24.9
|
-42.06
|
-53.02
|
-48.33
|
-49.62
|
-53.92
|
-61.04
|
Operating Margin
|
-
|
-229.79%
|
-395.01%
|
-521.75%
|
-482.21%
|
-564.91%
|
-613.04%
|
-574.25%
|
Earnings before Tax (EBT)
1 |
-
|
-29.91
|
-45.44
|
-56.67
|
-47.41
|
-48.32
|
-52.46
|
-59.83
|
Net income
1 |
-32.14
|
-29.91
|
-45.44
|
-56.67
|
-47.41
|
-48.23
|
-52.96
|
-58.33
|
Net margin
|
-
|
-276.03%
|
-426.67%
|
-557.69%
|
-473.04%
|
-549.08%
|
-602.12%
|
-548.81%
|
EPS
2 |
-19.40
|
-12.20
|
-10.00
|
-12.20
|
-8.960
|
-6.160
|
-4.598
|
-4.596
|
Free Cash Flow
1 |
-
|
-
|
-37.62
|
-
|
-38.43
|
-47
|
-55
|
-60
|
FCF margin
|
-
|
-
|
-353.26%
|
-
|
-383.46%
|
-535.11%
|
-625.33%
|
-564.49%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/20
|
16/03/21
|
24/02/22
|
13/03/23
|
08/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
3.135
|
2.057
|
2.393
|
2.825
|
2.887
|
2.297
|
2.197
|
2.833
|
2.696
|
2.086
|
2.064
|
2.302
|
2.327
|
2.545
|
2.6
|
EBITDA
1 |
-12.53
|
-15.1
|
-15.02
|
-12.54
|
-10.13
|
-11.56
|
-12.07
|
-12.3
|
-
|
-12.4
|
-12
|
-12
|
-12
|
-13
|
-13
|
EBIT
1 |
-12.57
|
-15.13
|
-15.06
|
-12.61
|
-10.22
|
-11.63
|
-12.14
|
-12.37
|
-12.2
|
-12.47
|
-12.61
|
-12.3
|
-12.34
|
-12.62
|
-13.25
|
Operating Margin
|
-400.86%
|
-735.68%
|
-629.38%
|
-446.23%
|
-354%
|
-506.18%
|
-552.48%
|
-436.57%
|
-452.49%
|
-597.75%
|
-611.22%
|
-534.12%
|
-530.54%
|
-495.87%
|
-509.62%
|
Earnings before Tax (EBT)
1 |
-13.62
|
-16.11
|
-15.94
|
-13.29
|
-11.33
|
-11.56
|
-11.96
|
-12.18
|
-11.71
|
-11.88
|
-12.51
|
-11.99
|
-12.04
|
-12.32
|
-13.16
|
Net income
1 |
-13.62
|
-16.11
|
-15.94
|
-13.29
|
-11.33
|
-11.56
|
-11.96
|
-12.18
|
-11.71
|
-11.88
|
-12.41
|
-12
|
-12.03
|
-12.32
|
-13.16
|
Net margin
|
-434.45%
|
-783.13%
|
-666.11%
|
-470.58%
|
-392.41%
|
-503.22%
|
-544.42%
|
-429.97%
|
-434.42%
|
-569.32%
|
-601.58%
|
-521.39%
|
-517.06%
|
-484.28%
|
-506.15%
|
EPS
2 |
-3.000
|
-3.600
|
-3.400
|
-2.800
|
-2.400
|
-2.400
|
-2.400
|
-2.130
|
-2.030
|
-2.050
|
-1.677
|
-1.500
|
-1.317
|
-0.7900
|
-0.8900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/02/22
|
05/05/22
|
04/08/22
|
09/11/22
|
13/03/23
|
04/05/23
|
03/08/23
|
02/11/23
|
08/02/24
|
07/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-37.6
|
-
|
-38.4
|
-47
|
-55
|
-60
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.68
|
-
|
0.42
|
-
|
1
|
1
|
1
|
Capex / Sales
|
-
|
6.25%
|
-
|
4.09%
|
-
|
11.39%
|
11.37%
|
9.41%
|
Announcement Date
|
19/03/20
|
16/03/21
|
24/02/22
|
13/03/23
|
08/02/24
|
-
|
-
|
-
|
Average target price
78
USD Spread / Average Target +1,030.43% Consensus |
1st Jan change
|
Capi.
|
---|
| -45.88% | 40.67M | | +19.41% | 45.51B | | -8.62% | 38.52B | | +38.65% | 38.13B | | +26.95% | 30.74B | | -13.50% | 26.03B | | +10.74% | 25.92B | | +44.87% | 14.13B | | +34.36% | 12.73B | | -7.14% | 11.29B |
Other Biotechnology & Medical Research
|